EASL 2011 Coverage - Highlights by HIV and Hepatitis.com of EASL 2011, Berlin, Germany

You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com

Sign up to receive our twice-weekly e-Newsletter

HIV and Hepatitis.com Coverage of the
46th Annual Meeting of the European
Association for the Study of the Liver
March 30 - April 3, 2011, Berlin, Germany

The material posted on HIV and Hepatitis.com about EASL 2011 is not approved by nor is it a part of EASL 2011.

	Library of Slides and Posters
	Hepatitis B Articles
	Hepatitis C Articles

Hepatitis C Articles

EASL Releases New Hepatitis C Clinical Practice Guidelines

Boosted ABT-450 Improves Early Response to Interferon for Hepatitis C

Tegobuvir Works Well in Triple and Quad Regimens for HCV

Boosted Danoprevir Improves Response in Prior Null Responders

Once-Daily BI201335 Ups Response to Interferon for Hepatitis C

BMS-790052/BMS-650032 Combo Cures Hepatitis C without Interferon

Statin Boosts Response to Pegylated Interferon/Ribavirin

Boceprevir Helps Hepatitis C Patients with Cirrhosis

TMC435 Beats Standard Therapy Regardless of HCV Genotype

Telaprevir Improves HCV Cure Rates Regardless of IL28B Status

Polymerase Inhibitor PSI-7977 Works with Interferon or Companion Drug

Pegylated Interferon Lambda Boosts Response with Few Side Effects

First Sustained Response Data for Polymerase Inhibitor Mericitabine

4-Drug Combo with Telaprevir and VX-222 Clears HCV at 12 Weeks

Telaprevir Combo Works for HCV Patients with Prior Unsuccessful Treatment

BMS-790052 + Pegylated Interferon/Ribavirin Works Well for First HCV Treatment

Cyclophilin Inhibitor Alisporivir Active Against HCV in Phase 2b, HBV in Lab

Hepatitis B Articles
	Kidney Toxicity Uncommon among People Taking Tenofovir for Hepatitis B
	HBV Genotype Predicts HBeAg Seroconversion on Tenofovir
	Immune-Based Therapy GS-9620 Shows Promise for Hepatitis B

Library of Slides and Posters
	Baseline Genotype And HBsAg Were Found To Have Signifi cant Association With HBeAg Seroconversion Following Up To 4 Years Of Tenofovir Disoproxil Fumarate Treatment J Heathcote and others. EASL 2011.
	Preclinical Characterization of GS-9620, A Potent and Selective Oral TLR7 Agonist D Tumas and others. EASL 2011.
	Therapeutic Efficacy of a TLR7 Agonist for HBV Chronic Infection in Chimpanzees R Lanford and others. EASL 2011.
	Anti-Viral Effi cacy and Induction of an Antibody Response Against Surface Antigen with the TLR7 Agonist GS-9620 in the Woodchuck Model of Chronic HBV Infection S Menne and others. EASL 2011.
	Impact of IL28B Genotype and Pre-treatment Serum IP-10 in Treatment-Naïve Genotype 1 HCV Patients Treated with TMC435 in Combination with Peginterferon a-2a and Ribavirin in the PILLAR Study J Aerssens and others. EASL 2011.
	Treatment outcome and resistance analysis in HCV genotype 1 patients previously exposed to TMC435 monotherapy and re-treated with TMC435 in combination with PegIFNa-2a/ribavirin O Lenz and others. EASL 2011.
	Pharmacokinetics of TMC435 in subjects with moderate hepatic impairment V Sekar and others. EASL 2011.
	The ASPIRE Trial: TMC435 in treatment-experienced patients with genotype 1 HCV infection who have failed previous PegIFN/RBV treatment: Week 24 interim analysis S Zeuzem and others. EASL 2011.
	First Report of SVR12 for a NS5A Replication Complex Inhibitor, BMS-790052, in Combination With PegIFNá-2a and RBV: Phase IIA Trial in Treatment-Naive HCV Genotype 1 Subjects S Pol and others. EASL 2011.
	A Phase 2b Trial Comparing 24 to 48 Weeks Treatment with Tegobuvir (GS-9190)/PEG/RBV to 48 Weeks Treatment with PEG/RBV for Chronic Genotype 1 HCV Infection E Lawitz and others. EASL 2011.
	Interim Results of a Randomized Treatment Study of Emtricitabine/Tenofovir DF (FTC/TDF) and HBIG Withdrawal in Post-Orthotopic Liver Transplant (OLT) Recipients for CHB L Tepperman and others. EASL 2011.
	Preclinical Properties of the Novel HCV NS3 Protease Inhibitor GS-9451 A Corsa and others. EASL 2011.
	Reduced Bone Mineral Density Derived from Dual X-ray Absorptiometry (DEXA) Assessments in Patients with Chronic Hepatitis B (CHB) S Fung and others. EASL 2011.
	Effects of Tenofovir DF on Renal Function of Chronic HBV Patients in Three Global Randomized Studies P Marcellin and others. EASL 2011.
	A Phase-I, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Escalating Oral Doses of GS-9620 In Healthy Subjects U Lopatin and others. EASL 2011.
	HBsAg Kinetics in Patients with Chronic Hepatitis B (CHB) Treated with Tenofovir Disoproxil Fumurate (TDF) for up to 4 years P Marcellin and others. EASL 2011.

EASL 2011 News